1. Home
  2. AUDC vs ESPR Comparison

AUDC vs ESPR Comparison

Compare AUDC & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AudioCodes Ltd.

AUDC

AudioCodes Ltd.

HOLD

Current Price

$8.36

Market Cap

267.0M

Sector

Utilities

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$2.72

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AUDC
ESPR
Founded
1992
2008
Country
Israel
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
267.0M
731.9M
IPO Year
2000
2013

Fundamental Metrics

Financial Performance
Metric
AUDC
ESPR
Price
$8.36
$2.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$12.50
$7.60
AVG Volume (30 Days)
102.1K
5.0M
Earning Date
05-05-2026
03-10-2026
Dividend Yield
4.83%
N/A
EPS Growth
N/A
60.71
EPS
N/A
N/A
Revenue
N/A
$403,135,000.00
Revenue This Year
$4.24
$2.92
Revenue Next Year
$2.18
N/A
P/E Ratio
$23.06
N/A
Revenue Growth
N/A
21.31
52 Week Low
$6.95
$0.73
52 Week High
$11.48
$4.18

Technical Indicators

Market Signals
Indicator
AUDC
ESPR
Relative Strength Index (RSI) 54.58 45.15
Support Level $8.13 $2.66
Resistance Level $8.75 $3.02
Average True Range (ATR) 0.23 0.19
MACD -0.00 0.04
Stochastic Oscillator 39.59 63.04

Price Performance

Historical Comparison
AUDC
ESPR

About AUDC AudioCodes Ltd.

AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: